Drug
Agomelatine
Agomelatine: highest development phase Phase 3, developed by Novartis. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Agomelatine (AGO178C) NCT01110889 | Phase 3 | Major Depressive Disorder |
| agomelatine NCT00467402 | Phase 3 | Major Depressive Disorder |
Latest
No recent events.
Follow Agomelatine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.